Home
Name
AIDA
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for AIDA
Name
Alternate Names
Aberel
Airol
All-trans-retinoic acid
Avita
Dermairol
Eudyna
Renova
Retin-A
Retinoic acid
Retisol-A
Stieva-A
Vesanoid
Vitamin A Acid
Vitinoin
Abbreviations
ATRA
Vit A
Category
Differentiation inducing agent
Subcategory
None
NSC Number
122758
Primary Site
Histology
None
Remarks
Tretinoin is FDA approved for treatment of acute promyelocytic leukemia (APL). It is a retinoid/differentiation agent and at this time the precise mechanism of action has not been fully elucidated so it cannot be assigned to chemotherapy, hormone or BRM/immunotherapy. Code this agent as treatment in the "Other Therapy" data field (using code 1).
Phase II (head & neck)
Administered topically, tretinoin stimulates epithelial turnover and reduces epithelial cell cohesiveness. Under investigation for treatment of Kaposi sarcoma lesions. FDA approved therapy of acute promyelocytic leukemia. NCI.Code this agent as treatment in the "Other Therapy" data field (using code 1).
Phase II (head & neck)
Administered topically, tretinoin stimulates epithelial turnover and reduces epithelial cell cohesiveness. Under investigation for treatment of Kaposi sarcoma lesions. FDA approved therapy of acute promyelocytic leukemia. NCI.Code this agent as treatment in the "Other Therapy" data field (using code 1).
Coding
Please see remarks for additional information
Name
Alternate Names
4-Demethoxydaunorubicin
Idamycin
Idamycin PFS
Idarubicin hydrochloride
IMI 30
IMI-30
SC-33428
Abbreviations
4-DMDR
IDA
Category
Chemotherapy
Subcategory
Antitumor antibiotic
NSC Number
256439
Primary Site
Chronic myelogenous leukemia in blast crises
Myelodysplastic syndromes (MDS)
Histology
None
Remarks
An anthracycline antineoplastic agent. FDA approved uses on acute lymphocytic and non-lymphcytic leukemia.
Coding
This drug should be coded
